Recent advances in CRISPR/Cas-based genome insertion technologies

IF 6.5 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Molecular Therapy. Nucleic Acids Pub Date : 2024-02-05 DOI:10.1016/j.omtn.2024.102138
Xinwen Chen, Jingjing Du, Shaowei Yun, Chaoyou Xue, Yao Yao, Shuquan Rao
{"title":"Recent advances in CRISPR/Cas-based genome insertion technologies","authors":"Xinwen Chen, Jingjing Du, Shaowei Yun, Chaoyou Xue, Yao Yao, Shuquan Rao","doi":"10.1016/j.omtn.2024.102138","DOIUrl":null,"url":null,"abstract":"<p>Programmable genome insertion (or knock-in) is vital for both fundamental and translational research. The continuously expanding number of CRISPR-based genome insertion strategies demonstrates the ongoing development in this field. Common methods for site-specific genome insertion rely on cellular double-strand breaks (DSBs) repair pathways, such as homology directed repair (HDR), non-homologous end joining (NHEJ) and microhomology mediated end joining (MMEJ). Recent advancements have further expanded the toolbox of programmable genome insertion techniques, including prime editing, integrase coupled with programmable nuclease, and CRISPR-associated transposon (CAST). These tools possess their own capabilities and limitations, promoting tremendous efforts to enhance editing efficiency, broaden targeting scope and improve editing specificity. In this review, we first summarize recent advances in programmable genome insertion techniques. We then elaborate on the cons and pros of each technique to assist researchers in making informed choices when utilizing these tools. Finally, we identify opportunities for future improvements and applications in basic research and therapeutics.</p>","PeriodicalId":18821,"journal":{"name":"Molecular Therapy. Nucleic Acids","volume":null,"pages":null},"PeriodicalIF":6.5000,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy. Nucleic Acids","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.omtn.2024.102138","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Programmable genome insertion (or knock-in) is vital for both fundamental and translational research. The continuously expanding number of CRISPR-based genome insertion strategies demonstrates the ongoing development in this field. Common methods for site-specific genome insertion rely on cellular double-strand breaks (DSBs) repair pathways, such as homology directed repair (HDR), non-homologous end joining (NHEJ) and microhomology mediated end joining (MMEJ). Recent advancements have further expanded the toolbox of programmable genome insertion techniques, including prime editing, integrase coupled with programmable nuclease, and CRISPR-associated transposon (CAST). These tools possess their own capabilities and limitations, promoting tremendous efforts to enhance editing efficiency, broaden targeting scope and improve editing specificity. In this review, we first summarize recent advances in programmable genome insertion techniques. We then elaborate on the cons and pros of each technique to assist researchers in making informed choices when utilizing these tools. Finally, we identify opportunities for future improvements and applications in basic research and therapeutics.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
基于 CRISPR/Cas 的基因组插入技术的最新进展
可编程基因组插入(或基因敲入)对于基础研究和转化研究都至关重要。基于CRISPR技术的基因组插入策略不断增多,表明了这一领域的不断发展。特异位点基因组插入的常见方法依赖于细胞双链断裂(DSB)修复途径,如同源定向修复(HDR)、非同源末端连接(NHEJ)和微同源介导末端连接(MMEJ)。最近的研究进展进一步扩大了可编程基因组插入技术的工具箱,包括质粒编辑、与可编程核酸酶结合的整合酶和 CRISPR 相关转座子(CAST)。这些工具都有各自的能力和局限性,促进了提高编辑效率、扩大靶向范围和改善编辑特异性的巨大努力。在这篇综述中,我们首先总结了可编程基因组插入技术的最新进展。然后,我们阐述了每种技术的利弊,以帮助研究人员在使用这些工具时做出明智的选择。最后,我们确定了未来在基础研究和治疗领域进行改进和应用的机会。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Molecular Therapy. Nucleic Acids
Molecular Therapy. Nucleic Acids MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
15.40
自引率
1.10%
发文量
336
审稿时长
20 weeks
期刊介绍: Molecular Therapy Nucleic Acids is an international, open-access journal that publishes high-quality research in nucleic-acid-based therapeutics to treat and correct genetic and acquired diseases. It is the official journal of the American Society of Gene & Cell Therapy and is built upon the success of Molecular Therapy. The journal focuses on gene- and oligonucleotide-based therapies and publishes peer-reviewed research, reviews, and commentaries. Its impact factor for 2022 is 8.8. The subject areas covered include the development of therapeutics based on nucleic acids and their derivatives, vector development for RNA-based therapeutics delivery, utilization of gene-modifying agents like Zn finger nucleases and triplex-forming oligonucleotides, pre-clinical target validation, safety and efficacy studies, and clinical trials.
期刊最新文献
Allele-specific CRISPR-Cas9 editing inactivates a single-nucleotide variant associated with collagen VI muscular dystrophy. CRISPR-Cas13d: RNA's own Jedi Master in the fight against viral darkness. Boosting CRISPR-Cas9 efficiency through enhanced homologous recombination. Engineered AAV capsid transport mutants overcome transduction deficiencies in the aged CNS Quality by design for mRNA platform purification based on continuous oligo-dT chromatography
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1